| Name | Title | Contact Details |
|---|
Launched in April 2020, Talkiatry provides accessible in-network psychiatric care. The technology-driven service is committed to providing the highest level of mental health care on an outpatient basis. Based in New York City, Talkiatry offers seamless telehealth as well as in-person care in thoughtfully-designed, upscale offices—all at affordable, in-network prices. Talkiatry accepts a wide-range of insurance and employs psychiatrists and psychiatric nurse practitioners curated from among the city`s finest healthcare providers.
HEALTHCARE NEEDS NEW ANSWERS Hospitals in the US are financially fragile and the pandemic has brought many to the verge of bankruptcy. Meanwhile, advancements in pharmaceuticals and medical technology carry the promise of better patient care – a...
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe`s leading biopharmaceutical companies, with a strong scientific core. Located in Switzerland – a biotech hub of Europe – Idorsia is specialized in the discovery and development of small molecules, to provide innovative therapeutic options.
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.
UI Magic Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.